Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epoprostenol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Single arm, open-label |
| Name | Type | Description |
|---|---|---|
| Epoprostenol | DRUG | Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit |
Inclusion Criteria: 1. Signed informed consent prior to initiation of any study-mandated procedure 2. Patients who completed participation in study AC-066A301 3. Patients who have not obtained access for commercial EFI at the time of ending participation in study AC-066A301 Exclusion Criteria: 1....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
Epoprostenol is used for the treatment of pulmonary arterial hypertension, a condition of high blood pressure in the arteries of the lungs. It is a small molecule being developed by Johnson & Johnson for this cardiovascular indication.
Epoprostenol is a small molecule that works as a vasodilator to widen blood vessels in the lungs, reducing the workload on the heart in patients with pulmonary arterial hypertension. It is being developed by Johnson & Johnson for this condition.
Epoprostenol is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker JNJ. The drug is intended for the treatment of pulmonary arterial hypertension.
Epoprostenol is in Phase 3 clinical development for pulmonary arterial hypertension. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 trial has been completed.
Epoprostenol has been studied in a Phase 3 clinical trial with the identifier NCT01470144, titled "Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension." This trial enrolled 41 participants and has been completed.
Epoprostenol is a synthetic form of prostacyclin, a naturally occurring substance that dilates blood vessels. It is being developed by Johnson & Johnson for pulmonary arterial hypertension and is currently in Phase 3 clinical development.